Pfizer reported first-quarter results that beat Wall Street expectations and reiterated its full-year outlook, as the drugmaker leans on newer products and pipeline investments to counter waning Covid-related revenue.

CNBC reported that Pfizer posted adjusted earnings per share of 75 cents on revenue of $14.45 billion, both above the consensus estimates tracked by LSEG. The company also reaffirmed its 2026 outlook, signaling confidence that newer launches and acquisitions can help stabilize growth as older franchises mature.

The market’s focus has shifted to how quickly Pfizer can replace lost Covid-era sales with durable revenue streams. Management has been emphasizing business development and R&D productivity, including targeted oncology programs and next-wave candidates that could contribute meaningfully over the next several years.

Pfizer’s reaffirmed outlook matters for investors because it reduces near-term uncertainty around earnings power and cash generation—two key inputs for large-cap pharma valuation. For the broader stock market, mega-cap healthcare earnings can influence sector leadership when cyclical groups are pressured by macro headlines.

Investors will be watching several themes through the rest of 2026:

1) Evidence that newer and acquired products are sustaining top-line growth.

2) Updates on pivotal clinical readouts that could expand Pfizer’s addressable markets.

3) Any changes to capital allocation priorities—such as buybacks, dividend policy, and further M&A—depending on cash flow and pipeline confidence.

While the report is not a market-wide macro catalyst on its own, it feeds into earnings-season positioning, where “beats plus reaffirmed guidance” have often been rewarded, especially in defensive sectors. The key question for Pfizer’s stock remains whether momentum from newer products can persist long enough to re-rate the shares as the company’s Covid exposure continues to fade from reported comparisons.